Hanmi’s Rosuzet achieves approx. KRW 20 billion sales only in a year

The Hanmi Pharm’s(CEO Kwan-Sun Lee) hyperlipidemia therapy ‘Rosuzet’ achieved approximately KRW 20 billion sales(Jan 2016 to Nov 2016, based on UBIST) in a year after the launch.

For the past 6 months, Rosuzet recorded monthly KRW 2.3 billion prescriptions and 2.2 million tablets, and has been prescribed in 323 major hospitals, like Seoul National University Hospital and Severance Hospital.

L...